Crescent Biopharma, Inc.
NASDAQ:CBIOBiotechnology
Healthcare
$12.40 -2.69%
-$0.49 today
- Market cap
- $482.30M
- Beta
- 1.15
- P/E (TTM)
- -3.3
- EPS (TTM)
- -$5.33
52W Low $8.72High $27.41
Volume 0.33M
Average 0.28M
Income Statement
Follow revenue through to earnings.
Revenue
$10.84M
FY 2025 · Annual
Operating Income
-$152.63M
FY 2025 · Annual
Net Income
-$153.94M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.16M | 75K | 10K | 0 | 10.84M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 1.16M | 75K | 10K | 0 | 10.84M |
| Gross Margin | 100.0% | 100.0% | 100.0% | — | 100.0% |
| Research & Development | 47.49M | 28.39M | 20.07M | 28.06M | 138.09M |
| Selling, General & Admin | 17.12M | 19.09M | 19.21M | 16.32M | 25.39M |
| Operating Expenses | 64.61M | 47.48M | 39.29M | 49.9M | 163.48M |
| Depreciation & Amortization | 264.6K | 207.15K | 153.3K | 35.17K | 84K |
| EBITDA | (63.18M) | (47.2M) | (39.12M) | (44.17M) | (149.67M) |
| EBITDA Margin | -5447.9% | -62927.6% | -391213.5% | — | -1380.2% |
| Operating Income | (63.45M) | (47.4M) | (39.28M) | (49.9M) | (152.63M) |
| Operating Margin | -5470.7% | -63204.4% | -392752.9% | — | -1407.5% |
| Interest Income | 19.77K | 714.52K | 2.38M | 1M | 2.88M |
| Interest Expense | 0 | 0 | 0 | 852K | 2.19M |
| Other Income / Expenses | 19.77K | 714.96K | 2.38M | 1.37M | 690K |
| Income Before Tax | (63.43M) | (46.69M) | (36.9M) | (48.52M) | (151.94M) |
| Pre-Tax Margin | -5469.0% | -62251.1% | -368987.8% | — | -1401.2% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 2M |
| Net Income | (63.43M) | (46.69M) | (36.9M) | (48.52M) | (153.94M) |
| Net Margin | -5469.0% | -62251.7% | -368994.2% | — | -1419.6% |
| EPS (Basic) | (1.23) | (0.89) | (0.58) | (1.40) | (14.78) |
| EPS (Diluted) | (1.23) | (0.89) | (0.58) | (1.40) | (14.78) |
| 51.45M | 52.53M | 63.34M | 19.5M | 10.41M | |
| 51.45M | 52.53M | 63.34M | 19.5M | 10.41M |
CBIO Earnings Waterfall · TTM
NASDAQ:CBIO · Revenue to Net Income
Key Ratios
EPS$-10.91
Gross Margin50.0%
Net Margin-773.2%
P/E Ratio-2.3
P/S Ratio139.9
Analysis
$11.9M of revenue converted into -$162.1M of net income for the selected period. Gross margin is 50.0% and net margin is -773.2%, showing how much revenue survives after costs and taxes. EPS is $-10.91, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 12, 2026 | |
| 10-Q | Quarterly report | Nov 12, 2026 | |
| SC 13G | SC 13G filing | Oct 27, 2026 | |
| 8-K | Current report | Oct 15, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 18, 2026 |
How much revenue does CBIO generate?
Crescent Biopharma, Inc. (CBIO) reported $10.84M of revenue in fiscal 2025.
Is CBIO profitable?
Crescent Biopharma, Inc. (CBIO) reported -$153.94M of net income, with a net margin of -1419.6%.
Continue the stock analysis
Jump to another research area for this company.